Carl Zeiss Meditec: The Second Lens
Carl Zeiss Meditec (CZM) was re‑valued using two opposite approaches: a top‑down probability‑weighted DCF that priced the whole company between €11 (bear) and €62 (bull) with a blended fair value of roughly €38, and a bottom‑up sum‑of‑parts analysis that dissected each business segment. Both methods converged on the same €38 (~$41) valuation, suggesting the market’s implied assumptions are internally consistent. The authors highlight that this alignment raises the probability of the estimate being correct, while also exposing the risk that shared biases could amplify errors. The piece underscores the difficulty of valuing a complex medical‑technology firm that the market currently undervalues.
Where Nobody’s Looking: Europe’s £400 Billion Graveyard of Forgotten Insurance Policies
Europe’s life‑insurance sector hides a £400 bn graveyard of closed‑book policies that most insurers view as dead weight. Specialized consolidators are buying these legacy portfolios at 17‑36% discounts, migrating them onto shared platforms, and extracting predictable cash flows for decades. The...
The Wellness Economy's Best-Kept Secret: A 75-Year-Old Finnish Compounder With 24% ROE
A 75‑year‑old Finnish sauna‑heater maker, the only pure‑play public company in a fragmented market, commands over 20% of global sauna‑heater sales and delivers a 24% return on equity. The global wellness economy, now valued at $6.8 trillion, fuels a $900 million sauna‑equipment...
The Boredom Baron Weekly Intelligence Briefing (March 20, 2026)
Three weeks into the Iran‑Qatar conflict, a strike on Qatar’s LNG facility has turned a geopolitical flashpoint into a structural energy supply crunch, prompting European leaders to warn of a multi‑year gas squeeze. Despite widening credit spreads, equity momentum loss,...
When the Supply Chain Breaks, Europe’s Boring Small Caps Quietly Win
The market narrative claims supply‑chain disruptions have crushed European small‑cap stocks, driving investors toward large U.S. mega‑caps. In reality, many European firms with modest market capitalisation have insulated earnings through diversified suppliers and localized production. Their valuations have fallen disproportionately,...
Ten Research Candidates Scored Against the Supply Chain Alpha Framework
Ten research candidates have been evaluated against a newly introduced Supply Chain Alpha Framework, a seven‑dimension scoring model built on live Koyfin data. The companion document, released exclusively to Founding Members, breaks down each score, flags weaknesses, and cites every...
The Giant Vending Machine Company Compounding at 15% With Zero Debt
A European maker of vertical storage units—often called giant vending machines—has been compounding earnings at roughly 15 % while carrying zero interest‑bearing debt. The firm boasts a sustained 35 %+ ROIC over three years, over 140 000 machines installed worldwide, and a near‑€1 billion...
Carl Zeiss Meditec: When the Thesis Gets Punched in the Mouth
In this episode, the host revisits his deep‑dive analysis of Carl Zeiss Meditec, using the company’s Q1 FY2025/26 earnings call as a live case study to demonstrate how investment theses should evolve with new data. He critiques the common practice...